-
公开(公告)号：US20250092157A1
公开(公告)日：2025-03-20
申请号：US18793635
申请日：2024-08-02
Applicant: University of Leicester , Omeros Corporation
Inventor： Nigel John Brunskill , Gregory A. Demopulos , Thomas Dudler , Hans-Wilhelm Schwaeble
Abstract: In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
公开(公告)号：US20240424091A1
公开(公告)日：2024-12-26
申请号：US18656093
申请日：2024-05-06
Applicant: University of Leicester , Omeros Corporation
IPC: A61K39/395 , A61K39/00 , A61P13/12 , C07K16/40
Abstract: In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
公开(公告)号：US20240352152A1
公开(公告)日：2024-10-24
申请号：US18633379
申请日：2024-04-11
Applicant: Omeros Corporation , University of Leicester
Inventor： Gregory A. Demopulos , Hans-Wilhelm Schwaeble , Thomas Dudler , Larry W. Tjoelker
CPC classification number: C07K16/40 , A61P27/02 , A61P35/04 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof.
-
4.发明公开公开(公告)号：US20240076408A1
公开(公告)日：2024-03-07
申请号：US18312891
申请日：2023-05-05
Applicant: Omeros Corporation , University of Leicester
Inventor： Hans-Wilhelm Schwaeble , Clark E. Tedford , James B. Parent
IPC: C07K16/40 , A61K39/395
CPC classification number: C07K16/40 , A61K39/3955 , A61K2039/505
Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
-
公开(公告)号：US11278300B2
公开(公告)日：2022-03-22
申请号：US16089755
申请日：2017-03-29
Inventor： Mohammad Reza Bahmanyar , David Adlam
IPC: A61B17/22
Abstract: A medical device for assisting the break-up, disruption or disintegration of calcified or other hardened material within vessels of the human or animal body which material otherwise prevents or inhibits stenting procedures or passage of guidewires, catheters and other devices through the vessels. The device includes a catheter having a lumen extending between a distal end and a proximal end of the catheter and a displaceable element at the distal end of the catheter configured for axial and/or radial displacement relative to the catheter when driven by pressure fluctuations within the lumen. A pressure pump is coupled to a proximal end of the catheter and is configured for application of a baseline pressure to the catheter lumen. A pressure modulation source is also coupled to the proximal end of the catheter, configured to modulate the baseline pressure in the catheter lumen with one or more pressure impulses, and preferably with a series of pressure pulses.
-
Patent Agency Ranking
公开(公告)号：US20220073885A1
公开(公告)日：2022-03-10
申请号：US17279058
申请日：2019-09-24
Applicant: UNIVERSITY OF LEICESTER
Inventor： Martha CLOKIE , Anisha THANKI
Abstract: There is provided a bacteriophage of the Myoviridae family, comprising a genome of circularly permuted double-stranded DNA at a length of 200kbp or more; characterised in that the phage has any one or more of the following features: a) does not have a holin gene; and/or b) binds to the Salmonella lipopolysaccharide; and/or c) has only one tail fibre protein; and d) has a sequence with at least 95% sequence identity to SEQ ID NO. 7 and/or a sequence with at least 80% sequence identity to SEQ ID NO.8. Suitably, the bacteriophage may be used to treat salmonella, in particular in the treatment of salmonella in pigs and fowl.
-
公开(公告)号：US10736960B2
公开(公告)日：2020-08-11
申请号：US15399524
申请日：2017-01-05
Applicant: University of Leicester , Omeros Corporation
Inventor： Nigel John Brunskill , Gregory A. Demopulos , Tom Dudler , Hans-Wilhelm Schwaeble
IPC: A61K39/395 , A61P13/12 , C07K16/40 , A61K39/00
Abstract: In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
公开(公告)号：US10401323B2
公开(公告)日：2019-09-03
申请号：US14912736
申请日：2014-05-13
Applicant: UNIVERSITY OF LEICESTER
Inventor： Marcus Cooke , Mahsa Karbaschi
IPC: G01N27/447 , G01N27/453
Abstract: This invention relates to a method of performing electrophoretic analysis on an substrate comprising: providing a substrate on a surface of at least one supporting member; and performing electrophoresis on the substrate by submerging the or each supporting member in an electrophoresis tank having a base and side walls enclosing a volume containing an electrophoresis buffer and inducing an electric current between ends thereof; wherein the or each supporting member is aligned within the tank such that each surface upon which the substrate is located is nonparallel with respect to the base of the electrophoresis tank and is substantially parallel with the direction of the electric current.
-
9.发明申请公开(公告)号：US20190127484A1
公开(公告)日：2019-05-02
申请号：US16131871
申请日：2018-09-14
Applicant: Omeros Corporation , University of Leicester
Inventor： Hans-Wilhelm Schwaeble , Gregory A. Demopulos , Thomas Dudler , Patrick Gray
Abstract: In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.
-
10.发明申请公开(公告)号：US20180291111A1
公开(公告)日：2018-10-11
申请号：US15909423
申请日：2018-03-01
Applicant: Omeros Corporation , University of Leicester
Inventor： Gregory A. Demopulos , Hans-Wilhelm Schwaeble , Clark E. Tedford , James Brian Parent
IPC: C07K16/40
Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
-
-
-
-
-
-
-
-
-
Search Results
147
records
(took 0.044 seconds)
